GT200000102A - Complejo farmaceutico. - Google Patents
Complejo farmaceutico.Info
- Publication number
- GT200000102A GT200000102A GT200000102A GT200000102A GT200000102A GT 200000102 A GT200000102 A GT 200000102A GT 200000102 A GT200000102 A GT 200000102A GT 200000102 A GT200000102 A GT 200000102A GT 200000102 A GT200000102 A GT 200000102A
- Authority
- GT
- Guatemala
- Prior art keywords
- complex
- eletriptan
- formulation
- same
- sulfobutileter
- Prior art date
Links
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 abstract 2
- 229960002472 eletriptan Drugs 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 229920001353 Dextrin Polymers 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 239000001202 beta-cyclodextrine Substances 0.000 abstract 1
- FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000002850 nasal mucosa Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
LA INVENCION SE REFIERE A UN COMPLEJO DE ELECTRIPAN (UNA METILPIRROLIDINA) Y A UNA SULFOBUTILETER BETA CICLODEXTRINA [MOSTRADO EN LA FIGURA I, DONDE "R" = OH O O(CH2)4) SO3 H], O A SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, Y A PROCEDIMIENTOS PARA LA PREPARACION DE TAL COMPLEJO, INCLUYENDO FORMULACIONES FARMACEUTICAS Y USOS DEL MISMO. EL ELETRIPTAN ES UN AGONISTA DEL RECEPTOR 5HT Y SE HA DEMOSTRADO ALTAMENTE EFICAZ PARA EL TRATAMIENTO DE LA MIGRAÑA, HIPERTENSION EMESIS, DEPRESION, DEPENDENCIA DE DROGAS. CON EL FIN DE ADMINISTRAR ELETRIPTAN, O UNA SAL DEL MISMO, POR VIA INTRANASAL, ES DESEABLE QUE LA FORMULACION NO PRODUZCA IRRITACION EN LA MUCOSA NASAL, CON ESE PROPOSITO SE LE HA AGREGADO EL COMPLEJO DE DEXTRINA, LOGRANDO UNA BUENA BIODISPONIBILIDAD Y UN COMIENZO DE ACCION RAPIDA; LA FORMULACION TAMBIEN INCLUYE COMPONENTES INDISPENSABLES COMO ANTIOXIDANTES Y EXCIPIENTES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9915231.6A GB9915231D0 (en) | 1999-06-29 | 1999-06-29 | Pharmaceutical complex |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200000102A true GT200000102A (es) | 2001-12-14 |
Family
ID=10856302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200000102A GT200000102A (es) | 1999-06-29 | 2000-06-22 | Complejo farmaceutico. |
Country Status (44)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9915231D0 (en) * | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
| NZ537995A (en) * | 2002-08-20 | 2007-11-30 | Bristol Myers Squibb Co | Inclusion complex of aripiprazole in a substituted b-cyclodextrin |
| GB0329918D0 (en) * | 2003-12-24 | 2004-01-28 | West Pharm Serv Drug Res Ltd | Intranasal compositions |
| CN1296391C (zh) * | 2004-03-04 | 2007-01-24 | 中国人民解放军第二军医大学 | 氟代羧烷基环糊精醚类化合物及其制备方法和应用 |
| GB0613925D0 (en) | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
| CN101957330B (zh) * | 2010-06-12 | 2013-10-09 | 南京巨环医药科技开发有限公司 | 磺丁基倍他环糊精含量的测定方法 |
| WO2017122161A1 (en) * | 2016-01-15 | 2017-07-20 | Cadila Healthcare Limited | An intranasal composition comprising 5ht1b/1d receptor agonists |
| WO2019143925A1 (en) * | 2018-01-22 | 2019-07-25 | Insys Development Company, Inc. | Liquid rizatriptan compositions |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| HU211648A9 (en) | 1990-03-28 | 1995-12-28 | Chinoin Gyogyszer Es Vegyeszet | Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same |
| HU210921B (en) | 1990-03-28 | 1995-09-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them |
| HU225055B1 (en) | 1990-10-15 | 2006-05-29 | Pfizer | Indole derivatives, their intermediates, process for production them and pharmaceutical compositions containing the compounds |
| RU2143896C1 (ru) | 1993-03-05 | 2000-01-10 | Хексаль Аг | Кристаллический комплекс циклодекстрина с гидрохлоридом ранитидина, способ его получения и содержащие его фармацевтические составы |
| MX9504664A (es) | 1994-03-07 | 1997-05-31 | Dow Chemical Co | Conjugados de dendrimeros bioactivos y/o dirigidos. |
| GB9417310D0 (en) | 1994-08-27 | 1994-10-19 | Pfizer Ltd | Therapeutic agents |
| US6255502B1 (en) | 1996-07-11 | 2001-07-03 | Farmarc Nederland B.V. | Pharmaceutical composition containing acid addition salt of basic drug |
| US5998462A (en) | 1996-12-16 | 1999-12-07 | Allelix Biopharmaceuticals Inc. | 5-alkyl indole compounds |
| GB9704498D0 (en) | 1997-03-05 | 1997-04-23 | Glaxo Wellcome Spa | Chemical compound |
| EP0999841B1 (en) | 1997-07-03 | 2001-10-17 | Pfizer Limited | Pharmaceutical compositions containing eletriptan hemisulphate and caffeine |
| GB9816556D0 (en) * | 1998-07-30 | 1998-09-30 | Pfizer Ltd | Therapy |
| GB9915231D0 (en) * | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
-
1999
- 1999-06-29 GB GBGB9915231.6A patent/GB9915231D0/en not_active Ceased
-
2000
- 2000-05-26 CO CO00039185A patent/CO5170494A1/es not_active Application Discontinuation
- 2000-06-02 NZ NZ515235A patent/NZ515235A/en unknown
- 2000-06-02 WO PCT/IB2000/000746 patent/WO2001000243A1/en not_active Ceased
- 2000-06-02 BR BR0011845-1A patent/BR0011845A/pt not_active Application Discontinuation
- 2000-06-02 CZ CZ20014572A patent/CZ20014572A3/cs unknown
- 2000-06-02 EE EEP200100697A patent/EE200100697A/xx unknown
- 2000-06-02 DE DE60018744T patent/DE60018744T2/de not_active Expired - Lifetime
- 2000-06-02 AP APAP/P/2001/002369A patent/AP2001002369A0/en unknown
- 2000-06-02 ES ES00929741T patent/ES2235879T3/es not_active Expired - Lifetime
- 2000-06-02 IL IL14634100A patent/IL146341A0/xx unknown
- 2000-06-02 MX MXPA01013274A patent/MXPA01013274A/es active IP Right Grant
- 2000-06-02 YU YU87501A patent/YU87501A/sh unknown
- 2000-06-02 TR TR2001/03827T patent/TR200103827T2/xx unknown
- 2000-06-02 SK SK1893-2001A patent/SK18932001A3/sk unknown
- 2000-06-02 UA UA2001129200A patent/UA66932C2/xx unknown
- 2000-06-02 CN CNB008097127A patent/CN1198654C/zh not_active Expired - Fee Related
- 2000-06-02 EA EA200101106A patent/EA003908B1/ru not_active IP Right Cessation
- 2000-06-02 PL PL00352902A patent/PL352902A1/xx not_active Application Discontinuation
- 2000-06-02 EP EP00929741A patent/EP1189640B1/en not_active Expired - Lifetime
- 2000-06-02 JP JP2001505950A patent/JP4454900B2/ja not_active Expired - Fee Related
- 2000-06-02 KR KR1020017016844A patent/KR20020015067A/ko not_active Ceased
- 2000-06-02 HR HR20010951A patent/HRP20010951A2/xx not_active Application Discontinuation
- 2000-06-02 DZ DZ013320A patent/DZ3320A1/fr active
- 2000-06-02 HU HU0201629A patent/HUP0201629A3/hu unknown
- 2000-06-02 CA CA002376847A patent/CA2376847C/en not_active Expired - Fee Related
- 2000-06-02 OA OA1200100328A patent/OA11964A/en unknown
- 2000-06-02 AT AT00929741T patent/ATE290884T1/de not_active IP Right Cessation
- 2000-06-02 GE GE4655A patent/GEP20043377B/en unknown
- 2000-06-02 AU AU47741/00A patent/AU770169B2/en not_active Ceased
- 2000-06-06 PA PA20008496801A patent/PA8496801A1/es unknown
- 2000-06-22 GT GT200000102A patent/GT200000102A/es unknown
- 2000-06-27 AR ARP000103223A patent/AR033337A1/es unknown
- 2000-06-27 UY UY26224A patent/UY26224A1/es not_active Application Discontinuation
- 2000-06-27 PE PE2000000648A patent/PE20010346A1/es not_active Application Discontinuation
- 2000-06-28 SV SV2000000112A patent/SV2002000112A/es unknown
- 2000-06-28 TN TNTNSN00142A patent/TNSN00142A1/fr unknown
- 2000-06-29 US US09/606,508 patent/US6713461B1/en not_active Expired - Fee Related
- 2000-06-29 EC EC2000003551A patent/ECSP003551A/es unknown
-
2001
- 2001-11-16 IS IS6163A patent/IS6163A/is unknown
- 2001-11-26 BG BG106151A patent/BG106151A/xx unknown
- 2001-12-20 ZA ZA200110454A patent/ZA200110454B/xx unknown
- 2001-12-24 MA MA26450A patent/MA26801A1/fr unknown
- 2001-12-28 NO NO20016430A patent/NO20016430L/no not_active Application Discontinuation
-
2004
- 2004-03-30 US US10/812,440 patent/US20040186076A1/en not_active Abandoned
-
2006
- 2006-04-13 JP JP2006111074A patent/JP2006257091A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY26910A1 (es) | Formulaciones de liberación sostenida para secretagogos de hormona del crecimiento | |
| UY26977A1 (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos | |
| ES2079210T3 (es) | Formulacion farmaceutica de aerosol. | |
| EA200400007A1 (ru) | ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ | |
| ES2164940T3 (es) | Forma de dosificacion solida bioadhesiva. | |
| NO20100041L (no) | Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorer | |
| AR018862A1 (es) | Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion | |
| ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
| ES2139132T3 (es) | Composiciones farmaceuticas activas en la terapia de desordenes del sueño. | |
| AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| ES2182161T3 (es) | Utilizacion de derivados de pirimidina para la preparacion de un medicamento para la prevencion del cancer. | |
| PA8559501A1 (es) | Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno | |
| AR044775A1 (es) | Composiciones farmaceuticas de atorvastatina | |
| UY27023A1 (es) | Derivados de fenil cetonas sustituidas como antagonistas de ip | |
| ECSP034826A (es) | Método para fabricar una composición farmacéutica de dosis baja | |
| ATE297730T1 (de) | Nasenspray enthaltend ondansetron-hydrochlorid | |
| PA8527901A1 (es) | Derivados de quinazolin como un antagonista del adrenèrgico alfa-1 | |
| AR023687A1 (es) | Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa | |
| MXPA04010860A (es) | Composiciones terapeuticas de 1,2,3,6-tetrahidropirimidin-2-ona y metodos para usarla. | |
| ATE311928T1 (de) | (-)-pseudoephedrin als sympathomimetisches arzneimittel | |
| CA2391968A1 (en) | An improved pharmaceutical composition for treating male erectile dysfunction | |
| PE20221595A1 (es) | Uso terapeutico de un conjugado de accion prolongada de un triple agonista que tiene actividad en todos los receptores de glucagon/glp-1/gip para enfermedades pulmonares | |
| ES2194618T1 (es) | Composicion oralmente desintegrable que comprende mirtazapina. | |
| BRPI0408113A (pt) | métodos para tratar ou prevenir um distúrbio do sistema nervoso central, para controlar um distúrbio do sistema nervoso central e para reduzir ou evitar um efeito adverso associado com a administração de um ingrediente ativo secundário em um paciente que sofre de um distúrbio do sistema nervoso central, e, composição farmacêutica | |
| PA8496801A1 (es) | Complejo farmaceutico |